Literature DB >> 31022774

Surgical and oncological outcomes after ultrasound-guided robotic liver resections for malignant tumor. Analysis of a prospective database.

Benedetta Pesi1, Luca Moraldi1, Francesco Guerra1, Federica Tofani1, Alessandro Nerini1, Mario Annecchiarico1, Andrea Coratti1.   

Abstract

AIM: Robotic surgery is thought to have a role in widening the application of minimally invasive liver surgery. Nonetheless, data concerning surgical results for liver malignancies are presently still lacking. We aimed to evaluate the surgical and oncological outcomes of ultrasound guided robotic liver resections for hepatic malignancies.
METHODS: All consecutive patients who received robotic resection of primary and secondary liver malignancies from September 2008 to January 2017 were analyzed. The same surgical team performed all procedures following the principle of parenchymal-sparing surgery.
RESULTS: From a total of 51 patients, 13 patients (25%) underwent major and 38 (75%) minor hepatectomy. No mortality occurred. Two procedures were converted to open surgery. Five patients experienced major complications, with a reintervention rate of 6%. Median hospital stay was 5 days.
CONCLUSIONS: Robotic surgery is a safe and feasible procedure for liver resection even when dealing with malignancies. Our data show that robotic surgery can be considered a valid option to treat patients with liver malignancies in a minimally invasive manner, without compromise the oncological results.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  colorectal liver metastasis; hepatocellular cancer; liver surgery; oncological outcomes; robotic surgery

Year:  2019        PMID: 31022774     DOI: 10.1002/rcs.2002

Source DB:  PubMed          Journal:  Int J Med Robot        ISSN: 1478-5951            Impact factor:   2.547


  1 in total

Review 1.  Augmented Reality and Image-Guided Robotic Liver Surgery.

Authors:  Fabio Giannone; Emanuele Felli; Zineb Cherkaoui; Pietro Mascagni; Patrick Pessaux
Journal:  Cancers (Basel)       Date:  2021-12-14       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.